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Abstract 
Since the introduction of cisplatin and other platinum-based drugs in cancer chemotherapy, 
metal complexes and organometallic compounds have been gaining growing importance in 
oncology. Recently, organometallic Ru(II) compounds bearing 1,3,5-triaza-7-
phosphaadamantane (pta), ethylendiamine, sugar- and maltol-derived ligands have shown 
promising anticancer properties with cytotoxicity comparable or in some case superior to 
cisplatin. Some of the compounds are even active in cisplatin resistance cell lines, probably 
due to different mode of actions. The content of this diploma project involves the synthesis of 
a series of novel M(II)-arene half-sandwich complexes (M=Ru, Os) with derivatives of 3-
hydroxy-2-pyridone ligands, characterization by standard methods such as NMR 
spectroscopy, ESI-MS, elemental analysis and determination of solid state structures by X-
ray diffraction analysis.  In vitro anticancer assays in human cancer cell lines will 
demonstrate the potential of the new compounds for further development. 
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Zusammenfassung 
Seit Cisplatin und andere auf Platin basierende Medikamente in die Chemotherapie zur 
Behandlung von Krebs eingeführt wurden, haben Metallkomplexe und organometallische 
Verbindungen wachsende Wichtigkeit im Bereich der Onkologie erhalten. In letzter Zeit 
haben Ru(II) Verbindungen, die Derivate von 1,3,5-triaza-7-phosphaadamantan (pta), 
Ethylendiamin, Zuckern und Maltol als Liganden besitzen, vielversprechende 
tumorhemmende Eigenschaften gezeigt. Die Zytotoxizität dieser Verbindungen ist 
vergleichbar mit und in manchen Fällen sogar höher als die von Cisplatin. Manche dieser 
Verbindungen sind sogar in Zelllinien aktiv, die gegen Cisplatin resistent sind. Dies ist 
möglicherweise auf eine andere Wirkungsweise der Substanzen zurückzuführen. Der Inhalt 
dieser Diplomarbeit beinhaltet die Synthese einer Serie von neuen M(II)-Aren Halb-sandwich 
Komplexen (M=Ru, OS) mit 3-Hydroxy-2-pyridon Derivaten als Liganden. Die 
Charakterisierung dieser Verbindungen erfolgte mit Standardmethoden, wie NMR 
Spektroskopie, ESI-MS, Elementalanalyse, und Analyse der Festkörperstrukturen durch 
Röntgen Diffraktionsanalyse. In vitro Antikrebsassays in humanen Krebszelllinien werden 
das Potential dieser neuen Verbindungen zeigen, woraus sich wiederum neue Konzepte für 
zukünftige Entwicklungen ableiten lassen. 
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1 Introduction 
 
1.1 Cancer 
 
Cancer – by definition a class of diseases – is one of the major causes of deaths worldwide. 
There might be the need to explain the difference between what is commonly known as 
cancer and for example a tumor. One speaks of a benign tumor when there is abnormal and 
uncontrolled growth of cells. It is called a malignant tumor under the following circumstances: 
The symptoms are coupled with invasion of the surrounding tissue by cancerous cells. 
Additionally the formation of metastasis occurs, where abnormal cells travel to different parts 
of the body – sometimes located far away from the original tumor – via the bloodstream and 
the lymphatic system. Only with these conditions the term cancer applies2. 
The starting point is a mutation in one single cell from which cancer can arise. This mutation 
comes either from genetics (5-10%) or is ascribed to external factors including lifestyle and 
environmental causes (90-95%)3 (Fig. 1). 
The latter can be categorized as follows: 
 Physical carcinogens, e.g. UV radiation 
 Chemical carcinogens, e.g. tobacco smoke 
 Biological carcinogens, e.g. infections from viruses like human papilloma virus (HPV) 
and its relation to cervical cancer, hepatitis B and liver cancer, and bacteria like 
heliobacter pylori and their relation to stomach cancer4 
 
As we are ageing our exposure to risk factors accumulates and our cells gradually lose their 
ability to repair themselves. This leads to the fact that the chance to develop cancer grows 
greatly with age. 
 
                                                            
2 US National Institute of Health, http://cancer.gov/cancertopics/understandingcancer, (4/2/2011) 
3 Anand P, et al. Pharm Res. 2008 September; 25(9): 2097–2116. 
4 WHO, Fact sheet N°297, February 2009 
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Fig. 1: The progression of cancer5 
 
Chemical Carcinogens 
Tobacco 
13 types of cancer can be attributed to smoking. Each additional cigarette smoked amplifies 
the risk proportionally. Carcinogenic substances in tobacco smoke include PAH and 
nitrosamines. Passive smoking, due to the chemical composition of the smoke, causes 10-
15% of lung cancers in never-smokers. Smokeless tobacco is also linked to cancers, i.e. oral 
cancers. Here the plausible cause for cancer is derived from the elevated level of 
nitrosamines (Fig. 2). 
 
Fig. 2: Tobacco can cause cancer not only when smoked but also when chewed or snuffed5 
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Alcohol 
In recent times a correlation between the consumption of alcohol and colorectal and breast 
cancer was derived additionally to the already confirmed links to liver cancer and cancers of 
the gastro-intestinal tract. This might be related to its ability to act as a solvent for 
carcinogenic compounds and a rise of the estrogen level. 
 
Biological Carcinogens 
Chronic infections and vaccinations 
Chronic infections differ in the way they disrupt the body which can lead to cancer. HPV 
interrupts biochemical pathways while Human Hepatitis B Virus (HBV), Human Hepatitis C 
Virus (HCV) and H. pylori are responsible for constant tissue inflammation (Fig. 3). HIV 
weakens the immune system leaving it vulnerable to carcinogenic infections. 
HBV and HPV vaccines have shown to be great tools in the prevention of cancer. The 
problem is to reach people who need it most, which is at least partially because of the high 
costs of the drugs. 
For infections like HCV, HIV and H. pylori, it is more likely to develop a vaccine against the 
formation of symptoms, e.g. chronic infection, than a prophylaxis against the disease itself.5  
 
Fig. 3: Carcinogenesis induced by HBV and HCV5 
 
Formation 
The relation between cell growth and cell death in healthy tissue is balanced, but in cancer it 
is in disarray. This can be traced back to either uncontrolled growth or a cell is no longer able 
to undergo apoptosis, the programmed cell death. Now cell division exceeds cell death and 
unlike in healthy tissue the newly generated cells do not lose their ability for further cell 
                                                            
5 World Cancer Report 2008 
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division. This results in augmentation of the overall number of cells with the capacity to divide 
still intact. The tissue generated from this continuous cell production is called tumor or 
neoplasm. As this process moves along, the tissue loses its normal arrangement (Fig. 4).2 
 
Fig. 4: Devices of Cancer5 
 
 
Classification 
The classification of cancer types derived from the origin of the abnormal cells are done as 
follows:  
Carcinoma, the type of cancer where the tumorous cells arise from epithelial cells, is the 
most common form of cancer. This category comprises lung, prostate, breast and colon 
cancer. 
Sarcoma is the name given to cancer developed from connective tissue, e.g. muscle, fat, 
cartilage and bone. 
Special types of cancer are lymphoma and leukemia because they do not form solid tumors. 
These cancers arise in the lymphatic system and the bone marrow, respectively. The 
abnormal growth of white blood cells in leukemia is subsequently found in the blood stream. 
To differentiate between the different forms of cancer, Latin prefixes are added to the name. 
Each prefix is derived from the location where the tumorous growth arised, e.g., myosarcoma 
is the term for cancer of the muscle.2 
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Statistics 
The types of cancer that are the most common causes of death are breast, lung, stomach, 
liver and colon cancer (Fig. 5). When the data is separated by gender, prostate cancer is the 
most common cancer in men and breast cancer the most common in women, the numbers of 
the other types of cancer mentioned before vary between men and women (Fig. 6). When 
looking at the data worldwide one can see that tobacco and alcohol use is a problem 
everywhere. In high-income countries additional cancer occurrences come from overweight 
and obesity, while in low- and middle-income countries they derive from low fruit and 
vegetable intake and chronic infections from Hepatitis B, C and Human Papilloma Virus 
(HPV), the latter leading to many cases of cervical cancer. Low- and middle-income 
countries have more than 70% of the world’s cancer fatalities.4 
 
 
Fig. 5: Most frequent cancers for both genders in Europe (left) and the world (right)6 
 
                                                            
6 GLOBOCAN 2008 (IARC) Section of Cancer Information (4/2/2011),  
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900 
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Fig. 6: Most frequent cancers in Europe: women (left) and men (right)7 
 
Prevention 
The development of cancer in more than 30% of cases could be prevented. Strategies for 
this include avoiding risk factors like the aforementioned tobacco and alcohol use, 
overweight and obesity, low fruit and vegetable intake, but also physical inactivity, urban air 
pollution, indoor smoke from household use of solid fuels, and sexually transmitted HPV 
infections. Vaccination against HPV and Hepatitis B, control of occupational hazards and the 
reduction of sunlight exposure help to lower the occurrence of cancer.4 
 
Outlook 
The projections for cancer to become the major cause of death worldwide are continuously 
increasing and it is estimated to reach 12 million deaths in 2030.4  
                                                            
7 GLOBOCAN 2008 (IARC) Section of Cancer Information (4/2/2011), 
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=994 
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1.2 Cancer Treatment 
 
The treatment of cancer can be divided into several categories, the main three being surgery, 
radiation therapy and chemotherapy. Other options include hormonal therapy, monoclonal 
antibody therapy and immunotherapy. The ideal first treatment option is the physical excision 
of the cancerous tissue. Sometimes this is impossible because of the location of the tumor, 
its type or stage of development. On the other hand the patient’s overall state of health is an 
important criterion, which influences the type of therapy chosen. Chemotherapy – as well as 
radiation therapy – can be used to reduce the tumor size to facilitate surgical removal or to 
reduce number and size of the metastases. The aim to reach is remission.8 This is the fact 
when both symptoms and signs of the disease have disappeared or decreased.9 
 
1.2.1 Surgery 
The practice of surgery as cancer treatment is known since the ancient Egyptians. Later it 
was disapproved by Hippocrates and was also condemned by the Christian church during 
the Middle Ages. Surgery is an important part of modern cancer management. On the one 
hand, diseases can be treated with surgery, sometimes before they turn into malignancies. 
On the other hand, healthy tissue can be excised prophylactically when the genetic risk 
factors are heightened. Furthermore, it is used as a diagnostic tool when tissue samples 
need to be collected for pathologists. Surgery is also a valuable part of the staging of cancer. 
Surgery as cancer treatment is the best option when the entire cancerous tissue can be 
excised. When the cancer is not easily accessible sometimes only the accessible part is cut 
out. Surgery can also be done in a palliative way. It is then used to improve the living quality 
of the patients by procedures like blocking of nerves, parenteral nutrition and the removal of 
obstructions.5 
 
1.2.2 Radiation Therapy 
X-rays, i.e. photons, are used in conventional radiotherapy to damage the DNA which leads 
to apoptosis.10 Radiation therapy can be chosen either as primary treatment option or in an 
adjuvant fashion, where it can work in a palliative or therapeutic way.5 At the moment three 
methods of radiation therapy are in use: External beam therapy, proton therapy and 
brachytherapy. The first two involve external treatment whereas the latter is also called 
internal radiotherapy. 
                                                            
8 C. M. Haskell, Cancer Treatment, Saunders, Philadelphia 2000 
9 US National Institute of Health, http://www.cancer.gov/dictionary?CdrID=45867 (11/3/2011) 
10 W.P. Levin, et al., British Journal of Cancer, 2005, 93, 849 – 854 
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External beam therapy uses high-energy X-rays to destroy the cancerous tissue and is 
commonly used for breast, colorectal, head and neck, lung, prostate and brain tumors.11 
In proton therapy the energy and dose can be applied extremely accurately due to the 
physical properties of the protons.10 Therefore the side effects are less severe because the 
protons release almost all of their energy when they get in contact with the cancerous tissue 
thus not releasing any exit dose to the surrounding healthy tissue. Subsequently a higher 
dose of radiation can be administered. This method finds its most useful application in the 
treatment of children. Leaving the surrounding tissue intact is of utmost importance because 
the body is still in the developing phase. The cancers treated this way include lung, prostate, 
brain, spinal or vertebral body tumors, skull base sarcomas, head and neck cancer, pediatric 
brain tumors and eye melanomas.12 
Brachytherapy applies ionizing radiation for the partial or total destruction of cancerous 
tissue.13 With this method the radioactive material is placed either directly inside, i.e. 
interstitial brachytherapy, or adjacent to the abnormal growth, i.e. contact brachytherapy.  
The advantages over external radiation treatment lie with the possibility of a higher 
administered dose of radiation applied to a smaller area during a shorter amount of time. 
Both the area to be treated and the time of the treatment can be reduced. It also offers the 
possibility of either permanent implantation of radioactive material or a temporary therapy 
with both high- and low-dose rates.14 Brachytherapy finds its application in the following 
areas: prostate, cervix, head and neck, skin, breast, gallbladder, uterus, vagina, lung, rectum 
and eye cancer.13 
 
1.2.3 Immunotherapy and monoclonal antibody therapy 
In immunotherapy the aim is to activate the immune system of the patient to destroy the 
tumor. Different strategies are in use at the moment including the injection of interferons, 
tumor antigens or dead cancer cells and the activation of the immune system through 
cytokines. 
If monoclonal antibody therapy is chosen as the treatment option, the patient’s immune 
system will be stimulated by an antibody with the ability to attach itself to the surface of 
                                                            
11 Radiological Society of North America, 2010, http://www.radiologyinfo.org/en/info.cfm?pg=ebt 
(20/1/2011), http://www.radiologyinfo.org/en/info.cfm?pg=protonthera (20/1/2011) 
12 Radiological Society of North America, 2010, 
http://www.radiologyinfo.org/en/info.cfm?pg=protonthera (20/1/2011) 
13 Radiological Society of North America, 2010, http://www.radiologyinfo.org/en/info.cfm?pg=brachy 
(20/1/2011) 
14 A. Gerbaulet (ed.) et al., The GEC ESTRO Handbook of Brachytherapy, 2002 
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cancerous cells by binding specifically to protein-receptors localized there.8 To take this 
measure even further, the antibodies can be combined with toxins or radionuclides.15 
 
1.2.4 Hormonal therapy 
The aim of hormonal therapy is to block the hormones that are involved in the expansion of 
tumors by inhibiting the binding of the hormones to the receptors (in case of prostate and 
breast cancer this comprises testosterone and estrogen, respectively). Tamoxifen is the most 
important estrogen receptor antagonist. The drug arimedex limits the estrogen production.5 
 
1.2.5 Chemotherapy 
Frequently cancers cannot be treated by surgery or radiotherapy. Then chemotherapy comes 
in as the best treatment option5 and it is chosen either as primary treatment or in an adjuvant 
way post-surgery, where it is applied either palliative or therapeutic. When it is necessary to 
use chemotherapy before the cancerous tissue can be removed surgically we speak of 
neoadjuvant chemotherapy. Chemotherapy will be applied against metastases to shrink the 
tumor and to reduce the possibility of the recurrence of the cancer. It involves the application 
of drugs especially developed to interfere with the tumor cells’ ability to replicate and to 
ideally leave the healthy cells intact.8 
 
Toxicity of chemotherapeutics  
The major disadvantage of the “anticancer drugs” available at the moment is their inability to 
differentiate between cancerous cells and other fast replicating cells, like epithelia of both 
hair and oral mucosa, bone marrow and gastrointestinal crypt cells. This results in various 
side effects which are correlated to the type of the administered drug. 
The fact that mutations are much faster accumulated in cancer cells compared to healthy 
cells seems to be responsible for the development of both cancer and drug resistance, which 
is the main cause of failure of chemotherapy.5 
One drug can also be applied to a spectrum of tumors and shows no differentiation between 
them.8 
 
Chemotherapeutics can be categorized as follows (not including all classes): 
DNA adductors bind covalently to the metal center of the nucleic acids. This leads to an 
obstruction of the synthesis of DNA or causes changes in the DNA structure. This category 
includes alkylating agents, cytotoxic metal complexes and mitomycin C.5 Alkylating agents, 
                                                            
15 T.A.Waldmann, Nat. Med., 2003, 9(3) 
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like nitrosoureas, attach an alkyl group to DNA via the N7 atom of guanine. This damage of 
the DNA leads to disruption of the replication.16 Cytotoxic metal complexes, like 
platinum(II) complexes, e.g. cisplatin, carboplatin and oxaliplatin bind covalently to the purine 
of the DNA and thus cause structural changes.17 Mitomycin C acts as a cross-linker of the 
complementary DNA strands, which leads to inhibition of the DNA replication. It can also 
work as a monofunctional alkylating agent.18 
 
Topoisomerase I and II inhibitors and antibiotics are used to prevent DNA from unwinding. 
This is achieved by binding and inhibition of the responsible enzymes, which leads to 
apoptosis. 
 
Mitotic inhibitors inhibit mitosis for which cancer cells are more perceptive than healthy 
cells. They are often derivatives of plant alkaloids and terpenoids and interfere with the 
movement and separation of chromosomes as they hinder the formation of microtubuli. They 
either prevent the formation of the tubulin scaffold or hinder its disintegration. Main 
representatives of this type of drugs are vinca alkaloids, taxanes, and epothilones.  
 
The similar structures of antimetabolites and of nucleobases of DNA help in chemotherapy 
as they disturb the cell’s metabolism leading to cell death. Methotrexate was one of the first 
developed antimetabolites. It inhibits dihydrofolate reductase and therefore the synthesis of 
thymidine (Fig. 7). Another example is 5-fluorouracil, which is converted into 5-
fluorodeoxyuridine monophosphate. This leads to inhibition of the synthetic pathway of the 
DNA. 
 
Fig. 7: Mode of action of methotrexate5 
                                                            
16 D. Jensen, et al., Biochemistry, 1978, 17, 5098–5107 
17 L. Kelland, Nat. Rev. Cancer, 2007, 7, 573-584. 
18 M. Tomasz, Pharmacol. Ther., 1997, 76, 73-87 
 23 
 
Combination therapy is the term for treating the patients with more than one 
chemotherapeutic agent at once to tackle cancer cells by hitting several targets. Most of the 
time two or three drugs are combined to yield an effect.5 
A very common application of combination therapy is FOLFOX, where oxaliplatin is 
combined with 5-fluorouracil and leucovorin. This combination shows a higher activity against 
metastatic colon cancer than 5-fluorouracil and leucovorin without the platinum complex. 
Oxaliplatin on its own has no activity against this type of cancer.17 
 
Summarizing, according to the world cancer report 2008, 20-30 cytotoxic drugs are in use. 
They are frequently combined to yield better results. Unfortunately the drugs often possess 
severe side effects including damages to both kidney and nerves and tumors are becoming 
resistant against treatment. These drugs are the reason the survival rate of some types of 
cancer, for example testicular, breast and colorectal cancer, could be enhanced 
considerably. Due to getting more and more insight into the mode of action, new drugs can 
be developed.5 
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1.3 Metal-based Anticancer Drugs 
 
1.3.1 Introduction 
Metal ions, in particular transition metal ions, play an invaluable part in biological systems. 
Although organic compounds take the leading role in medicinal chemistry, metal-based drugs 
have picked up momentum in this field and find application in both diagnostics and curative 
treatment.19 
 
1.3.2 Platinum Compounds 
Modern chemotherapy is unthinkable without the three Pt complexes which have gained 
worldwide approval for clinical practice: cisplatin, carboplatin and oxaliplatin.19 (Fig. 8) 
 
 
Fig. 8: Timeline: Platinum compounds as anticancer drugs17 
 
Cisplatin is still one of the best drugs for treating ovarian and testicular cancers despite its 
nephrotoxicity. The severe side effects of cisplatin were the reason to search for a drug with 
the same effectiveness but considerably lower side effects. This led to the discovery of 
carboplatin. The mode of action of both drugs relies on forming bonds between the drug and 
DNA resulting in apoptosis. The development of oxaliplatin can be lead back to the need for 
a drug to treat cancers that are resistant to cisplatin.17  
 
                                                            
19 C.G. Hartinger, et al., Journal of Inorganic Biochemistry, 2006,100, 891–904 
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1.3.2.1 Cisplatin 
The development of cisplatin occurred serendipitously in the 1960s. Barnett Rosenberg, a 
physicist working at Michigan State University, was eager to investigate if bacterial growth 
can be stimulated by magnetic dipole or electric fields. The setup for the experiment included 
Escherichia coli and platinum electrodes and the bacteria started a filamentous growth. This 
could be traced back not to the effects of the electric field but to the experimental conditions 
and to the platinum electrodes, where accidentally cis-diamminedichloridoplatinum(II) was 
being synthesized. This byproduct, better known as cisplatin (Fig. 9), has already been 
prepared by Michele Peyrone in 1844. After his discovery Rosenberg tested the cytotoxicity 
of cisplatin first on various bacteria and after that on mice and proved its healing properties 
against solid tumors. In the early 1970s clinical trials were started by the US National Cancer 
Institute. At the end of this decade the FDA had already approved cisplatin under the name 
of Platinol®.17 The main field of application for cisplatin is ovarian and testicular cancer, but it 
is also used in the treatment of cervical, bladder and bronchogenic carcinoma, gastric and 
head and neck cancer as well as osteosarcoma.20 
 
 
Fig. 9: Structure of cisplatin 
 
The process of the cellular uptake of cisplatin is not thoroughly understood, though passive 
distribution and active transport by copper transporters are considered important; the 
following mode of action is proposed: Activation of cisplatin occurs in the cell and results 
from the exchange of one of the two chloride group with water. Afterwards it is able to form 
covalent DNA adducts. It does this by forming a bond with the N7 of guanine and also to the 
other purine based nucleobase, i.e. adenine, but not to same extent. This results in 
monofunctional or bifunctional adducts, most of the time with neighboring nuceotides forming 
crosslinks. The platinum-DNA adducts can have different effects on the DNA, e.g. bending 
and unwinding and this can also hinder mechanisms like transcription and replication.17 
 
                                                            
20 M. Galanski, et al., Current Medicinal Chemistry, 2005, 12(18), 2075-2094(20). 
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1.3.2.2 Carboplatin 
The discovery of cisplatin and its tumor-inhibiting abilities led to the development of a great 
number of platinum compounds. Approximately 30 of them, including carboplatin, i.e. cis-
diammine(1,1-cyclobutanedicarboxylato)platinum(II) (Fig. 10),  and oxaliplatin, were tested in 
clinical trials. Studies demonstrated that the change in leaving group from the chloride ligand 
in cisplatin to 1,1-cyclobutanedicarboxylate in carboplatin causes the compound to be more 
stable, exhibiting lower side effects, while obtaining the same activity. The FDA approved 
carboplatin under the name Paraplatin® for palliative application in 1989 and for first line 
treatment of ovarian cancer in 1991.17 
The coordination of carboplatin to the N7 of the DNA was proven by experiments involving 
the model compound 5’-GMP. These experiments, though in cell free environment, 
demonstrated differences to cisplatin like the lack of monoadduct formation and hydrolysis of 
products, which lead to the conclusion that carboplatin does not need to be activated by 
hydrolysis before application.21 
   
 
 
 
 
 
 
 
Fig. 10: Structure of carboplatin    Fig. 11: Structure of oxaliplatin 
 
1.3.2.3 Oxaliplatin 
In the late 1970s, a platinum compound was synthesized incorporating a 1,2-
diaminocyclohexane (DACH) ligand, namely [(1R,2R)-
diaminocyclohexane](oxalato)platinum(II), better known as oxaliplatin (Fig. 11). It is active 
against cisplatin resistant tumors and was FDA approved by the end of the millennium. It is 
available under the trade name Eloxatin®. Oxaliplatin is one of the components of FOLFOX, 
used very commonly in combination therapy to treat metastatic colorectal cancer.17 It causes 
other types of DNA damages than cisplatin, which can be related to the size and structure of 
the ligand.22 
 
                                                            
21 A. Küng, et al., J. Inorg. Biochem. 2001, 83, 181-186. 
22 M.A. Jakupec, et al., Rev. Physiolog. Biochem. Pharmacol., 2003, 146, 1-53 
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1.3.3 Non-platinum Compounds 
 
1.3.3.1 General Overview 
Due to the severe side effects of platinum compounds and their use limited to special forms 
of tumors, the search for other metal compounds with tumor-inhibiting properties is crucial.19 
New drugs need to have improved selectivity and activity, their toxicity should be lower and a 
new mode of action would be preferable.23 At the moment two non-platinum tumor-inhibiting 
compounds show great promise in clinical trials: tris(quinolinolato)gallium(III) (KP46) (Fig. 12) 
and indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019).24 
 
Fig. 12: Structure of KP46 
 
1.3.3.2 Ruthenium Compounds 
An encouraging alternative to platinum is provided by ruthenium complexes due to their well 
understood chemistry and the advancing comprehension of their biological activities.19 The 
main advantages of ruthenium complexes as drug candidates are believed to be related to 
their ability to mimic iron, their ligand exchange rate and the fact that several oxidation states 
are available under physiological conditions.25 
 
NAMI-A and KP1019 (Fig. 13) differ from most of the tumor-inhibiting pharmaceuticals that 
are based on platinum in the following points: ruthenium complexes are octahedral whereas 
platinum(II) compounds are square-planar and the Ru(II)/Ru(III) redox couple is reversible 
                                                            
23 W. Kandioller et al., J. Organomet. Chem., 2011, 696, 999-1010 
24 M. Hanif, et al., Inorg. Chem. 2010, 49, 7953–7963 
25 C.S. Allardyce, et al. Platinum Metals Rev., 2001, 45(2), 62-69. 
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whereas when Pt(IV) complexes are reduced to Pt(II) the interatomic bond distances as well 
as the coordination number change. As a result differences in the mode of action regarding 
these drugs are proposed. This could account for the capability of KP1019 to be effective 
against tumors resistant to cisplatin. Another advantage for ruthenium chemotherapeutics is 
their lower toxicity which could be explained by the ability of ruthenium(III) complexes to work 
as prodrugs, which means that they are converted into their active species in vitro or in vivo. 
 
         
Fig. 13: Structures of KP1019 (left) and NAMI-A (right), two Ru(III) complexes in clinical trials 
 
After learning of the antitumor effects of ruthenium red in the 1970s and the examination of 
fac-[RuCl3(NH3)3] and cis-[RuCl2(NH3)4]Cl as the first ruthenium antitumor agents in the early 
1980s, KP1019 and (H2im)[trans-RuCl4(Him)(dmso)] (NAMI-A, Him=imidazole) are the first 
tumor-inhibiting drugs with ruthenium as their metal center that are in clinical trials (Fig. 14). 
The results of preclinical experiments show very different points of application for these two 
anticancer drugs. KP1019 is active against different primary explanted human tumors and 
colon carcinomas while NAMI-A displayed effective results in the inhibition of metastasis. 
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Fig. 14: Proposed mode of action for KP1019 19 
 
Transferrin and albumin are the most important potential binding partners of Ru(III) 
compounds when given intravenously because drugs that contain transition metals show a 
high affinity to their soft sulfur and nitrogen donors.26 However, the initial binding event is 
related to hydrophobic interactions.27 
 
It is speculated that the large accumulation of Ru(III) complexes in tumors might be ascribed 
to transferrin. This protein is responsible for the transport of iron, for which the need is much 
higher in tumor cells than in healthy cells and therefore more iron receptors are expressed. 
This leads to the notion of transferrin as a “Trojan Horse” accountable for the transport of the 
ruthenium complex into the cell whether in the place of or additionally to the much needed 
iron. The current notion contains the exchange of the ligand with the histidine of the iron-
binding pocket and so forming a covalent bond between complex and transferrin.26 Albumin 
on the other hand is believed be used as storage for the medication as the greater part of 
ruthenium complexes (80-90%) is bound to this protein while in the blood stream.19  
 
1.3.3.3 Ruthenium(II)-arene compounds 
Ru(II)-arene compounds along with their corresponding Os(II)-arene analogues can be 
designed to tune important factors like chemical reactivity and pharmacological 
characteristics, including oral bioavailability, pharmacokinetic behavior, water solubility and 
stability in plasma. This can be achieved by choosing different ligands.24 
 
 
                                                            
26 M. Grössl, et. al., Electrophoresis 2009, 30, 2720–2727 
27 N. Cetinbas, et. al., J Biol Inorg Chem 2010, 15, 131–145 
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Due to the stabilizing properties of the η6-coordination of the aromatic ligand, Ru(II)-arene 
complexes are stable enough to come into consideration for appliance as a drug. Additionally 
the Ru(II) complex is positively affected by the arene so that both biological and 
physicochemical attributes are changed.23 These Ru(II)-arene complexes can be written as  
[Ru(η6-arene)(X)(Y)(Z)] (Fig. 15). X and Y are non-leaving ligands whereas Z is a 
monofunctional leaving group.28 The most commonly used leaving group is a halide, which 
promotes aquation. This helps the compound to react to biological targets.23 The geometry of 
these complexes is described as “piano stool” configuration. This derives from its 
appearance, where the arene serves as the seat of the piano stool and the legs are made up 
by the ligands.28  
 
Fig. 15: General structure of Ru(II)-arene complexes 
 
The idea behind the first organometallic ruthenium chemotherapeutics was the incorporation 
of bioactive ligands into the metal-arene complex. The first tests were conducted with [Ru(η6-
C6H6)Cl2(metronidazole)] given the fact that metronidazole is a well known anti-infective 
agent.24 Another early investigated compound was [Ru(η6-C6H6)Cl2(dmso)], which possesses 
topoisomerase II inhibiting properties, but only in high concentrations.23  
 
These initial results led to the development of compounds with various enzyme inhibitors as 
ligands like ethacrynic acid, paullones and staurosporine. On the other hand the use of non-
cytotoxic ligands like 1,3,5-triaza-7-phosphatricyclo[3.3.1.]decane (pta) and ethylenediamine 
resulted in compelling anticancer activity.24 The pta complexes are known as the RAPTA 
family. The pta ligand amplifies the aqueous solubility and the activity towards metastases.23 
When carbo- and oxaliplatin analogous are formed by exchanging the chlorido ligands with 
cyclobutane-1,1-dicarboxylate or oxalate, the resulting complexes show similar activity as the 
parent compounds, yet they are of minor in vitro anticancer activity. 
 
 
                                                            
28 R.E. Morris, et.al., J. Med. Chem. 2001, 44, 3616-3621 
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Complexes bearing bidentate ligands with O,O-, N,N-, N,O-, and S,O- donor systems in the 
form of a [M(η6-arene)(XY)Cl]n+ metal-arene complex (n = 0, 1) were evaluated on their 
cytotoxic properties. The use of compounds like ethylenediamine as N,N-ligands coordinated 
to Ru(II)-arene gave high cytotoxic values even in cell lines resistant to cisplatin.24 The 
studies demonstrated highest activity in cancer cell lines of complexes bearing the 
tetrahydroanthracene ligand and lowest activity with benzene derivatives. This shows that 
the chelating ligand has a high significance and impact with regard to biological, physical and 
chemical attributes of Ru(II) complexes.23 The discussed mode of action involves a hydrogen 
bond and monofunctional covalent binding to DNA nucleobases, but without any clear 
comprehension of the ultimate targets of bioorganometallics the topic remains discussed with 
much controversy.24 Neutral complexes can be formed by substituting ethylenediamine with 
acetylacetonate. The Ru(II) center of these compounds has a higher electron density, which 
promotes hydrolysis and the exchange of ligands, Ethylenediamine complexes bind 
preferably to guanine while on the other hand acetylacetonate complexes favor adenine.23 
Using paullone as N,N-chelating ligands coordinated to Ru or Os reveals high activity in vitro 
independent of the metal center. The use of O,O- and N,O-chelating ligands such as amino 
acids and derivatives in similar metal complexes yielded only moderate cytotoxicity, but 
picolinato and picolinamide ligands show great promise regarding their in vitro activities even 
in cells resistant to cisplatin.24 
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1.3.3.4 Maltol-derived compounds 
An important group of ligands are derivatives of maltol (Fig. 16) which are bound to the metal 
center of both di- and trivalent metal ions via an O,O-chelating moiety. The resulting 
complexes are more stable than with acetylacetonato ligands and exhibit minor cytotoxicity.29 
This can be ascribed to the fact that a ruthenium-hydroxo dimer, which is formed in aqueous 
solution, is a very stable but inactive species. This disadvantage can be overcome by 
replacing maltol with 3-hydroxypyrone derivatives, which include groups having both 
lipophilic and aromatic properties. Similar to platinum compounds, the interactions of these 
ruthenium-arene complexes with DNA were examined with 5’-GMP and demonstrated 
reactivity to the N7 of guanine.30 
  
Fig. 16: Structure of maltol 
 
3-Hydroxy-2-methyl-4-pyridones have been investigated as ligands for both mononuclear 
and dinuclear ruthenium complexes. Dinuclear complexes in the form of PyrRu2n, with n as 
the chain length of the alkyl spacer, displayed encouraging cytotoxicity. The cytotoxicity 
correlates with the length of the spacer, which is related to the hydrophobicity of the 
compound and probably facilitates the cellular uptake. The dinuclear ruthenium(II)-arene 
complex showing the best results was PyrRu212 (Fig. 17) with activities higher than cisplatin 
and in the same range as oxaliplatin.31 The two chloride ligands are easily exchanged with 
water. As with the other compounds before, guanine is the binding site of choice and results 
in inter-duplex cross-linked DNA adducts with good stability.32 
 
                                                            
29 A. Peacock,  et al., Chem. Eur. J. 2007, 13 (9), 2601-2613. 
30 W. Kandioller, et al. J. Organomet. Chem. 2009, 694, 922-929. 
31 M. Mendoza-Ferri, et al., Organometallics 2008, 27, 2405-2407. 
32 O. Nováková, et al., Biochem. Pharmacol. 2009, 77, 364-374. 
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Fig. 17: Structure of PyrRu212 
 
For mononuclear complexes the substitution of O,O- with S,O-chelating ligands results in 
higher in vitro anticancer activity which can be deduced from their increase in stability when 
biomolecules are present.33 The anticancer activity of pyridones used instead of pyrones is 
high and shows promising results for overcoming drug resistance.24 
                                                            
33 W. Kandioller, et al., Chem. Eur. J. 2009, 15, 12283-12291. 
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1.4 Hydroxypyr(id)ones (HP) 
 
1.4.1 Introduction 
Hydroxypyridones have increasingly become of interest in medicinal inorganic chemistry. 
Their anions are able to build stable metal complexes with various metals thus showing great 
versatility as chelating ligands. During the last years there have been miscellaneous studies 
regarding hydroxypyridones and hydroxypyridone complexes. These involved using HP as 
anticancer drugs, matrix metalloprotein inhibitors, magnetic resonance imaging (MRI) 
contrast agents and anthrax lethal factor inhibitors. Also their use as antidiabetic, 
antibacterial, antiviral agents and as Na+- and Li+-receptors, as well as a treatment for manic 
depression was studied.34 Furthermore, hydroxypyridones, especially 1,2-dimethyl-3-
hydroxypyrid-4-one, i.e. deferiprone, are currently in use as therapeutics against iron-
overload diseases.23 They are also under discussion for treating misplaced iron and 
aluminium in neurodegenerative disorders such as Parkinson’s (PD) and Alzheimer’s (AD) 
diseases.35 
 
Fig. 18: Possible sites for derivatization of pyrones23 
 
Hydroxypyridones display favorable bioavailability and toxicity profiles. Additionally their 
lipophilic properties and the fact that their metal ion complexes are notably stable make 
hydroxypyridones an interesting compound class. 
 
There are three classes of hydroxypyridones known, i.e., 3-hydroxy-2-pyridone, 3-hydroxy-4-
pyridone, and 1-hydroxy-2-pyridone. The structure of hydroxypyridones contains the 
following elements: a secondary or tertiary amino group and a hydroxyl group ortho to a 
ketone. The amino group is easily functionalized and therefore a likely place to alter 
                                                            
34 M. Hanif, et al., Inorg. Chem., 2010, 49 (17), 7953–7963 
35 M. Amélia Santos, et al., Coord. Chem. Rev., 2008, 252, 1213–1224. 
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biological and physicochemical properties, like lipophilicity, oral bioavailability and chelating 
ability (Fig. 18). 36  
In recent times thiopyridones became of interest as S,O-metal chelating agents because 
their affinity to softer metal ions is higher than the one of the O,O-counterparts as is the 
stability of the complexes.23 
 
1.4.2 Selected Applications in Medicinal Inorganic Chemistry 
 
1.4.2.1 Treatment of iron deficiency and overload 
The control of iron concentration in cells, called “iron homeostasis”, is very important due to 
the fact that deficiency as well as overload of this essential trace element can create 
complications in the body.37 The affinity of 3-hydroxypyridones towards iron is high38 thus 
being suitable candidates for the treatment of iron overload diseases by substituting the 
moiety at the pyridone’s nitrogen while keeping the chelating properties.39 The 
aforementioned deferiprone was synthesized at the beginning of the 1980s40 and its clinical 
application started at the end of the millennium.41 One major advantage is that it can be 
taken orally.42 It was discovered that 85% of deferiprone was inactivated by O-glucuronation 
during the metabolism and excreted through the urine. Due to these findings it became a 
challenge to find new pyridone-derivatives lacking this particular inactivation.43 
People affected by iron deficiency have the need to enhance their diet with iron supplements. 
This can be problematic due to the potential toxicity of Fe(III), the oxidation state of iron when 
bound to transferrin. Said toxicity occurs because of a much higher production of reactive 
oxygen species (ROS).44 The difference of Fe(III) and Fe(II) is that under physiological 
conditions Fe(III) is hydrolyzed and precipitates.45 On the other hand Fe(II) has to be dosed 
very highly in order to reach the desired effects.46 When complexes of Fe(III) and maltol 
derivatives are formed, these drug compounds have favorable properties as compared to 
administration of iron salts. These include non-toxic ligands, neutral complexes and a more 
                                                            
36 K. H. Thompson, et al., Chem. Soc. Rev., 2006, 35, 545–556 
37 G. Papanikolaou, et al., Toxicol.Appl. Pharmacol., 2005, 202, 199-211. 
38 W.C. Tsai, et al., Biochem. Soc.,1973, 2, 70. 
39 W. Schlindwein, et al., Dalton Trans., (2006), 1313-1321. 
40 G.J. Kontoghiorghes, et al., Inorg. Chim. Acta, 1987, 136, L11-L12. 
41 A.V. Hoffbrand, et al., Blood, 2003, 102, 17-24 
42 S. Singh, et al., Drug Metab. Dispos.,1992, 20, 256-261. 
43 Z.D. Liuet al., J. Med. Chem., 1999, 42, 4814-4823. 
44 M.A. Barrand, et al., J. Pharm. Pharmacol., 1990, 42, 279-282 
45 T. Hedlund, et al., Acta Chem. Scand. Ser. 1988 A A42, 702. 
46 B. Morgan, et al., Chemosphere, 2007, 68, 2080-2084. 
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stable intermediate, hindering hydrolysis and the formation of iron precipitates.45 The main 
advantage of these complexes is their bioavailability in vivo, which allows to administer lower 
doses to patients in comparison to treatment with FeSO4.47  
 
1.4.2.2 Treatment of Alzheimer’s disease (AD) 
The goal of the application of pyr(id)ones in the treatment of AD is to chelate Al(III) to reduce 
its influences on the brain and thus the progression of Alzheimer’s disease.48 Al(III) is 
particularly dangerous because of its similarity to Fe(III) with regard to their coordination 
chemistry. Since investigations into [tris(maltolato)aluminum(III)] (Fig. 19) revealed 
neurotoxicity, the current focus lies on 3-hydroxypyridones because of their stronger 
complexation properties. 49 
 
Fig. 19: Al(III) maltolato complex 
 
1.4.2.3 Treatment of Diabetes 
Two maltol-based compounds, namely [bis(maltolato)oxovanadium(IV)] (BMOV) (Fig. 20) 
and [bis(ethylmaltolato)oxovanadium(IV)] (BEOV) have reached clinical phase II trials as 
potential treatment of type-2 diabetes.50 The insulin mimicking property of vanadium has 
been known since the 1980s but its use has been limited by the low bioavailability of its 
inorganic salts.51 Other maltol-based ligands have been coordinated to metals like Mo(VI),52 
                                                            
47 D.G. Maxton, et al., Br. J. Nutr., 1994, 71, 203-207 
48 D.R. Crapper, et al., Brain,1976, 99, 67-80 
49 M.M. Finnegan, et al., Inorg. Chem., 1987, 26, 2171-2176 
50 A. Sheela, et al., Eur. J. Med. Chem., 2008, 43, 2206-2210 
51 K.H. Thompson, et al., J. Inorg. Biochem., 2009, 103, 554-558 
52 S. Chaves, et al., Metallomics, 2010, 2, 220-227 
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Cu(II), Co(II)53 and Zn(II). The first three showed a lower activity than BMOV and BEOV, but 
the last showed promising results with (thio)pyr(id)onate as ligand both in vitro52 and in vivo.54  
 
Fig. 20: BMOV, M=VO 
 
1.4.2.4 Diagnostic use 
Today nearly a third of all MRI examinations require the use of paramagnetic metal ions, like 
Gd(III), as contrast agents to get clearer images. A good way to reduce the toxic effects of 
this metal is to bind it to multidentate ligand systems, but to leave one coordination site 
minimum accessable for an aqua species. The availability of coordination sites for aqua 
ligands is of the utmost importance to yield the desired contrast improvement. The higher the 
number of available coordination sites is, the better the contrast will be.55 When employing 
such compounds the resulting complexes will gain in relaxivity and do not lose their stability. 
Following this assumption, MRI contrast agents, involving Gd(III) with trisbidentate 
hydroxypyridonato ligands, have been developed,56 where six coordination sites of Gd(III) are 
taken by these ligands leaving two sites free to bind water molecules.57 One of the first 
pyridone-based ligands assessed when coordinated to Gd was tris[(3-hydroxy-1-methyl-
2(1H)-pyridone-4-carboxamido)ethyl]amine. The Gd(III) complex showed improved relaxivity 
as well as stability in comparison to the contrast agents that were already in use.58 Different 
linkers were used to determine the optimal parameters.57 The complexes were also tested in 
vivo yielding the highest success rate when two59 or three 57 water molecules were present in 
the inner coordination sphere.60 
 
                                                            
53 K.H. Thompson, et al., J. Inorg. Biochem., 2004, 98, 683-690 
54 A. Katoh, et al., J. Inorg. Biochem., 2009, 103, 567-574 
55 S. Aime, et al., Adv. Inorg. Chem., 2005, 57, 173-237 
56 A. Datta, et al., Acc. Chem. Res., 2009, 42, 938-947 
57 E.J. Werner, et al., J. Am. Chem. Soc., 2007, 129, 1870-1871 
58 J. Xu, et al., J. Am. Chem. Soc., 1995, 117, 7245-7246 
59 K.N. Raymond, et al., Bioconjug. Chem., 2005, 16, 3-8 
60 M.K. Thompson, et al., J. Med. Chem., 2005, 48, 3874-3877 
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1.4.2.5 Tris(maltolato)gallium(III) as potential anticancer drug 
Ga(III) compounds were on the one hand already in use for the imaging of soft tumor tissue 
and bear tumor inhibiting characteristics.61 On the other hand they possess an analogous 
coordination chemistry to Fe(III) and hence could use the same biochemical transport 
pathways.26 Therefore it was not farfetched to examine them as potential anticancer drugs. 
The biggest difference between Ga(III) and Fe(III) is the redox inertness of Ga(III) thus 
destabilizing biological functions when replacing Fe(III) in redox-active enzymes. The FDA 
approved gallium nitrate under the name GaniteTM for treating cancer related hypocalcaemia. 
During its clinical trials it proved to be active against bladder cancer and lymphoma. Due to 
the grave side effects, which include the drug being both nephrotoxic and neurotoxic, and its 
reduced bioavailability no further investigation were performed.62 The new focus was put on 
other ligands with the ability to increase the bioavailability of the gallium complex and to 
prevent the compound from hydrolyzing. This search concluded in clinical trials of gallium 
maltolate, i.e. [tris(maltolato)gallium(III)]. The advantages of gallium maltolate lie in its ability 
of oral administration and better bioavailability as compared to gallium salts. It completed 
phase I 63 but was terminated in phase I/II.64 
                                                            
61 R.E. Coleman, Cancer, 1991, 67, 1261-1270 
62 C.R. Chitambar, Curr. Opin. Oncol., 2004, 16, 547-552 
63 L.R. Bernstein, et al., Met. Based Drugs, 2000, 7, 33-47 
64 http://clinicaltrials.gov/show/NCT00050687 (26/6/2011) 
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1.4.3 Coordination Chemistry 
 
The structure of a hydroxypyridone contains a 6-membered N-heterocycle and has 
zwitterionic “aromatic” character (Fig. 21).  
 
Fig. 21: Mesomeric forms, X=O, N-R; Y=S,O 
3-Hydroxy-2-pyridones and 3-hydroxy-4-pyridones have O,O-chelating properties. Therefore 
and because of their strong affinity to metal ions they serve as likely ligands to form stable 
complexes. The formed 5-membered ring is thermodynamically stable at physiological pH 
values.65 The complex stability decreases in the following order: 3-hydroxy-4-pyridone, 3-
hydroxy-2-pyridone, and 1-hydroxy-2-pyridone and the complexes formed by pyridones are 
more stable than their pyrone analogues.66  
 
1.4.4 Synthetic considerations 
1.4.4.1 (Thio)hydroxypyr(id)ones 
The most general approach to convert hydroxypyrones into hydroxypyridones involves the 
protection of the hydroxyl group. This is done via benzylation and assists the progress of 
conversion. To obtain the product in high yield, it is very important to maintain the pH value 
at approximately 12 during the reaction with the primary amine. The last step includes the 
cleavage of the protection group via hydrogenation (Fig. 22).66 
 
Fig. 22: Reaction conditions: a) BnBr, b) H2N-R, c) H2, Pd/C 
 
To prepare the thionated analogues of 3-hydroxy-4-pyr(id)ones, approaches include (a) 
adding 1 eq of Lawesson’s reagent67 or (b) reacting them with P4S10 in excess.68  
                                                            
65 R.D. Hancock, et al., Chem. Rev., 1989, 89, 1875 
66 P.S. Dobbin, et al., J. Med. Chem., 1993, 36, 2448-2458 
67 S. Chaves, et al., Dalton Trans., 2008, 1773-1782 
68 V. Monga, et al., Inorg. Chem., 2005, 44, 2666-2677 
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2 Results and Discussion 
 
The research during my diploma thesis was aimed at the synthesis of 3-hydroxypyridone-
derived compounds and their Ru(II)(η6-arene) complexes with tumor-inhibiting properties.  
 
2.1 Synthesis and Characterization of the Ligands 
 
2.1.1 Synthesis 
The ligands were prepared in several steps. First, compound (c) has to be prepared from 
which (d) and (e) can be derived, which includes a protection step to yield (c). Afterwards 
ester (c) was converted into amides (d). Subsequently the protection group was removed by 
hydrogenation resulting in ligand (e) which then can be coordinated to different metal ions. 
 
 
(1) R= Propyl 
 
(2) R= 
 
 
(3) R= 
 
(4) R= 
 
Fig. 23: General procedure for the synthesis of the ligands 
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The synthesis of the ligand 1-[(ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-pyridone (b) was 
done by N-alkylation of 3-hydroxy-2-pyridone with an alkyl halide, e.g. ethyl bromoacetate, 
which also acts as a solvent in this reaction.34 This results in the formation of the ethyl ester. 
The next step is the protection of the hydroxyl group yielding 3-benzyloxy-1-carboxymethyl-2-
pyridone (c) in a SN2 reaction (Fig. 24). To get to the ether, we used an alkyl halide. e.g. 
benzyl chloride and an alkoxide anion, e.g. the pyridone anion. The pyridone serves as a 
good nucleophile and chloride as the leaving group. In this case NaOH is strong enough to 
be used as a base. 69 
 
Fig. 24: SN2 reaction – scheme 69 
The most important step in the preparation of the ligands was the exchange of the ester 
moiety with an amine forming the respective amides (d). The mechanism is shown in Fig. 25. 
The ester (A) is hydrolyzed under alkaline conditions (B) and reacts with 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) under formation of the reactive O-
acyl-N,N,N’,N’-tetramethyluronium intermediate (C). The formed active ester (D) reacts with 
the respective amines (E) yielding amides (F).70 To make the ligand ready for complexation, 
the protecting group has to be removed (Fig. 23-(e)). This deprotection step uses catalytic 
hydrogenation to cleave off the benzyl protecting group using hydrogen gas and a palladium 
catalyst. The removal of benzyl ethers can also be done by acids, where the conjugate base 
is nucleophilic.69 
 
Results: 
The goal of this part of the synthesis was to obtain straightforward procedures, which do not 
need harsh conditions and result in high yields. 
 
 Amide formation 
The yields ranged from 66 - 87%. All coupling steps were done following this synthetic 
strategy. After successful preparation of the respective ligands, another amide formation 
procedure was evaluated in a very small scale yielding ligand 1d’. This included the use of 
                                                            
69 J. Clayden, et al.; Organic Chemistry, Oxford University Press, 2001 (8) 
70 S. Fuchs; Oberflächenfunktionalisierte Poly(amidoamin)-Dendrimere als potentielle Trägermoleküle 
für Cytostatika, 2004 
 42 
 
N,N'-dicyclohexylcarbodiimide and N-hydroxysuccinimide instead of TBTU and of 
diisopropylethylamine as base. The interesting part of this alternative synthesis route is not 
the reduction of the reaction time by two hours, but the lack of need for the purification by 
solvent extraction. 
 
 Deprotection 
This step yielded approximately 70% of the desired product. The preferred procedure 
involved the use of an autoclave apparatus, only not applied when the respective ligand was 
not soluble in the highest usable amount (250 ml) of solvent, e.g. methanol and acetic acid, 
for the autoclave apparatus, as in case of compound 3e. The insolubility of ligand 3e can be 
attributed to the phenylbenzylamido moiety and its aromaticity. 
 
Fig. 25: Reaction mechanism for the preparation of the amide (Fig. 23-d) from the ester (Fig. 23-c) 70 
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2.1.2 Characterization 
 
The characterization of the prepared compound was carried out by 1H- and 13C{1H}-NMR 
spectroscopy in d6-DMSO, d4-MeOH and CDCl3. 
 
1H-NMR spectroscopy 
The -NH- of the amides were found around 10 ppm (singlet). Signals with chemical shift of 9 
ppm were assigned to the -OH group of the pyridone. The appearance of this peak in NMR 
spectra recorded in d6-DMSO is a clear indication that the deprotection was successful. The 
signals of the aromatic protons of the benzyl protection group can be found at approximately 
6.9 and 7.5 ppm. In some cases they overlapped with aromatic protons of the respective 
amide, e.g. 2d (Fig. 26). The protons of the pyridone ring can be found at approximately 7.3, 
7.2 and 7.0 ppm, with the H in meta position showing up as a dd. The two protons of the O-
CH2- group of the protection group are detected at around 5 ppm. Lack of these peaks is 
another indicator for a successful deprotection. The Npyr-CH2- group is found at 4.7 ppm. The 
signals of the aliphatic components of the amide moiety appear high field < 4 ppm. 
 
 
Fig. 26: Comparison of 1H NMR spectra: 2d (protected) and 2e (unprotected) 
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13C{1H}-NMR spectroscopy 
The resonances of the two C=O groups appear at around 170 and 160 ppm, followed by the 
quaternary groups at approximately 129 ppm and at higher field the –CH2- groups. The 
signals assignable to the aromatic carbon atoms are found between 131 and 75 ppm. 
 
2D-NMR spectroscopy 
In order to assign the peaks unambiguously 2D NMR spectroscopy studies were conducted. 
Different 2D methods are in use, e.g. 1H,1H-COSY, HSQC and HMBC. With 1H,1H-COSY, i.e. 
Correlation Spectroscopy, we are able to identify the proton-coupling and see if they are 
neighboured or spin coupled. In order to assign protons bound to carbon atoms at larger 
structural features, the coupling of carbon atoms and protons was recorded by HMBC (Fig. 
31) and HSQC. HSQC, i.e. Heteronuclear Single Quantum Coherence provides information 
about the coupling of carbon atoms and protons over a single bond. To collect the 
information on the coupling of carbon atoms and protons separated by two to four bonds 
HMBC, i.e. Heteronuclear Multiple Bond Coherence, can be applied. 
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2.2 Synthesis and Characterization of the Complexes 
 
2.2.1 Synthesis 
For the preparation of complexes 1f-11 (Fig. 27 and 28), the ligands were activated by 
sodium methoxide in methanol. Subsequently the dimer [(η6-arene)MX(µ-X)]2 (M = Ru, Os, X 
= Cl, Br, I) in dichloromethane was added and the reaction mixture was stirred for a minimum 
of 3 h at r.t. Purification was achieved by recrystalization from diethyl ether.29 
 
Results 
The yield of the chlorido complexes was around 60%. The complexation of the ligands with 
p-cymene was straight-forward while using biphenyl as arene proved to be more difficult and 
often did not work. When substituting the clorido leaving group with either bromide (1f’’, 2f’’) 
or iodide (1f’, 2f’) the yield of the complexes was much lower. 
 
The following ligands were used in the complexation 
 3-hydroxy-2-pyridone derived amides to yield their respective Ru(II)-arene complexes 
(1-4) (Fig. 27)  
 
 
 
 
 
(1f)  R= Propyl 
M= Ru 
X= Cl 
Arene= p-cymene 
(1f‘) R= Propyl 
M= Ru 
X= I 
Arene= p-cymene 
(1f‘‘) R= Propyl 
M= Ru 
X= Br 
Arene= p-cymene 
 
(2f)  R= 
M= Ru 
X= Cl 
Arene= p-cymene 
(2f‘)  R= 
M= Ru 
X= I 
Arene= p-cymene 
(2f‘‘)  R= 
M= Ru 
X= Br 
Arene= p-cymene 
 
(3f)  R= 
M= Ru 
X= Cl 
Arene= p-cymene 
(4f)  R= 
M= Ru 
X= Cl 
Arene= p-cymene
Fig. 27: Complexation of amides 
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 1,2-dimethyl-3-hydroxy-4(1H)-(thio)pyridones, which were kindly provided by 
Muhammad Hanif, to yield Ru(II)- and Os(II)-arene complexes (5-11) (Fig. 28) 
 
(5) 
 
 
 
 
 
  
 
(6)  (7) 
  
(8) 
 
(9) 
 
 
 
 
 
 
(10) 
 
(11)  
 
 
 
Fig. 28: 1,2-Dimethyl-3-hydroxy-4(1H)-(thio)pyridone-M(II)arene complexes 
 
2.2.2 Characterization 
 
The characterization was carried out by 1H- and 13C{1H}-NMR spectroscopy, melting point 
and elemental analysis. d4-MeOH and CDCl3 were used as solvents because the ruthenium 
complexes decomposed slower than in d6-DMSO. 
 
When measuring the melting points most of the complexes decomposed at temperatures 
>200 °C. The elemental analysis data collected for the complexes were in general in good 
agreement for the theoretical values. The only exception was a deviating oxygen value in 2f’’. 
The NMR spectra of 2f and 2f’’ showed that the protons in the N-CH2-CO group were non-
equivalent and were found at ca 5.22 and 4.35 ppm. For the complexes with the iodide 
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leaving group the NMR showed hindered rotation of the p-cymene probably due to the size of 
the iodide. 
The spectra of 1f, 1f’’, 2f’, 2f’’, 3f and 8 showed impurities due to traces of ligand still being 
present. 
The complexes with the 1,2-dimethyl-3-hydroxy-4(1H)-(thio)pyridone ligands were difficult to 
purify. While using the same recrystallization step as with all the other complexes resulted in 
the precipitation of the desired product, the complexes were not sufficiently soluble in 
solvents such as CDCl3 and d4-MeOH. Efficient characterization by NMR spectroscopy was 
not achievable, even though the elemental analysis confirmed the expected composition of 
the compound. For 7 the values found for C, N and H in elemental analysis were out of the 
acceptable range. 
 
1H-NMR spectroscopy 
The spectra of the ligands and the respective complexes are difficult to compare in terms of 
chemical shift because they were not recorded in the same solvent. 
The aromatic protons of the cymene are found in the range of 5.3-5.6 ppm. The only 
exception was the iodide complex with all 4 protons non-equivalent due to the steric 
hindrance of the rotation. The –CH-CH3 proton is found as a multiplet at approximately 3 
ppm. The –CH-CH3 methyl groups appear in the lower ppm range. 
 
 
Fig. 29: Structure of the p-cymene moiety 
 
13C{1H}-NMR spectroscopy 
Chemical shifts of the coordinated ligands are similar to those found in the spectra for the 
free ligands. The signals of 2f, which are representative of the cymene signals, are detected 
as follows: the -CH- groups are found at 80 (C2/C6), 78 (C3/C5) and 31 ppm (C7) The -CH3 
groups are found at 22 ppm (C8/C9) and 19 ppm (C10). The two quaternary carbon atoms are 
detected at 99 (C1) and 96 ppm (C4) (Fig. 29). 
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ppm (t2)
0.01.02.03.04.05.06.07.08.0
Fig. 30: Spectra of 6: 1H (top) and 13C{1H} (bottom) 
2D-NMR Spectroscopy 
The same methods as with the 2D NMR of the ligands were used to perform the 
measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31: 2D HMBC spectrum of 2f 
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2.3 Characterization overview 
compound 1H-NMR 13C{1H}-NMR 
Elemental 
Analysis 
Melting point 
[°C] 
Yield [%] 
1d      87 
1d‘      
1e     209-211 71 
1f 
impurities 
(ligand) 
   137-142 60 
1f‘       9 
1f‘‘ 
impurities 
(ligand) 
    10 
2d      211-212 66 
2e      246-247 72 
2f       decomp 64 
2f‘ 
impurities 
(ligand) 
    41 
2f‘‘ 
impurities 
(ligand) 
    35 
3d      203-204 73 
3e      236-237 72 
3c 
impurities 
(ligand) 
noise   decomp 65 
4d      70 
4e      69 
4f    67 
5        
6        
7        
8 
impurities 
(ligand) 
      
9        
10         
11        
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3 Conclusions and Outlook 
 
Developing new tumor inhibiting drugs is very important, due to the fact that the number of 
cancer patients and deaths is extremely high and steadily increasing. Compounds with 
different modes of action are tested in the hope to find a successful way to cure cancer. A 
relatively new class of compounds involves the use of hydroxypyridone ligands coordinated 
to metal centers, which are of great interest for the medical community as pyridones are 
already applied in various areas of medicine. 
 
During the course of this diploma thesis new Ru(II)-arene complexes substituted with 
hydroxypyridone ligands have been synthesized and different approaches to the synthesis of 
this type of complexes were tested. 
 
Fig. 32: General procedure for the synthesis of the complexes 
 
First, two precursors (b) and (c) had to be synthesized in large quantities. The main part of 
the synthesis (Fig. 32) comprised the amide formation (d), where the amine was coupled to 
the hydroxypyridone backbone, followed by a deprotection step from the benzyl group (e), 
and the complexation of the activated ligand to ruthenium with η6-p-cymene as arene and a 
chlorido leaving group (f). In addition, complexes with both iodido and bromido leaving 
groups were prepared. 
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Another part of this thesis was the synthesis of 1,2-dimethyl-3-hydroxy-4(1H)-(thio)pyridone-
M(II)arene complexes (Fig. 33). Here the arene was not only p-cymene and biphenyl, but 
also toluene and benzene. Again complexes with chlorido as well as bromido and iodido 
leaving groups were prepared. Additionally the oxygen of the pyridone was exchanged with 
sulfur resulting in thiopyridone and ruthenium was also replaced with osmium. 
 
Fig 33: 1,2-Dimethyl-3-hydroxy-4(1H)-(thio)pyridone-M(II)arene complexes 
 
This lead to a number of complexes with only small differences, which could be interesting 
for pinpointing the influences of various parts of the complexes and thus gaining more 
knowledge on the tumor-inhibiting effects of these compounds. 
 
It would be of great interest to see if these types of complexes exhibit cytotoxic properties. 
On the synthetic level it would be good to impove isolation and purification. 
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4  Experimental 
 
4.1 Materials and equipment 
 
The chemicals were purchased at analytical grade from commercial providers. Dry solvents 
were produced following standard procedures. Bis[dichlorido(η6-p-cymene)ruthenium(II)],  
bis[diiodido(η6-p-cymene)ruthenium(II)], bis[dibromido(η6-p-cymene)ruthenium(II)],  
bis[dichlorido[(η6-biphenyl)ruthenium(II)], bis[dichlorido(η6-toluene)ruthenium(II)],  
bis[dichlorido(η6-benzene)ruthenium(II)], 1,4-dihydrobiphenyl,71 and thiomaltol72 were 
synthesized according to literature procedures. 
A Bruker FT-NMR Avance III 500 MHz spectrometer was used to record the 1H (500.10 MHz) 
and 13C{1H} (125.75 MHz) as well as the 2D NMR spectra at 25 °C. 
A Büchi B-540 apparatus was used to determine the melting points. 
Samples for elemental analysis were submitted to the Microanalytical Labratory, University of 
Vienna. These samples were measured on a Perkin–Elmer 2400 CHN Elemental Analyzer. A 
Bruker esquire3000 was used to record the electrospray ionization mass spectra. 
 
  
                                                            
71 M.G. Mendoza-Ferri, et al., Organometallics 2009, 28, 6260–6265 
72 J.A. Lewis, et.al., Inorg. Chem. 2003, 42, 7455-7459 
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4.2 Synthesis 
 
4.2.1 Precursors 
 
1-[(Ethoxycarbonyl)methyl]-3-hydroxy-2-(1H)-pyridone 
A mixture of ethyl bromoacetate (83.5 g, 0.5 mol) and 3-hydroxy-2(1H)-pyridone (11.1 g, 0.1 
mol) was purged with Ar and heated until refluxation under Ar for 24 hours. Precipitation 
occurred when the solution was kept at 4 °C. The crude product was isolated by filtration and 
recrystallization from ethanol, which yielded yellow crystals. Yield: 15.2 g (77%)73 
 
3-Benzyloxy-1-carboxymethyl-2-pyridone 
Benzyl chloride (25 g, 0.2 mol) was added to a solution of 1-[(ethoxycarbonyl)methyl]-3-
hydroxy-2-(1H)-pyridone (10 g, 0.05) in a mixture of methanol:water (9:1 v/v). The 
adjustment to pH 12 was done with a sodium hydroxide solution, which was further added 
during the course of the reaction to maintain a pH > 12. Refluxation over night yielded a clear 
orange solution, which was cooled at room temperature. Methanol was removed on the 
rotary evaporator. Afterwards, the product was extracted with dichloromethane to remove 
benzyl chloride. Addition of water to the aqueous phase and acidification with concentrated 
hydrochloric acid to pH 2 resulted in the precipitation of the product. The solution was cooled 
by further addition of water. The product was separated by filtration and recrystallization from 
ethanol. Yield: 10.8 g (83 %)73 
 
4.2.2 General Procedures 
 
 Amide formation 
Dry 4-methylmorpholine was added to a solution of 3-benzyloxy-1-carboxymethyl-2-pyridone 
and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) in dry DMF 
under Ar and stirred at RT for 20 min. Subsequently the respective amine was added and the 
reaction occurred while stirring for another 18 hours at RT. DMF was removed under 
vacuum. The resulting product was dissolved in dichloromethane and purified by extraction 
with 5% aqueous HCl (2x), 5% aqueous NaOH (3x) and water (2x). The solvent was 
removed on the rotary evaporator and the crude product was recrystallized from 96% 
ethanol.74 
                                                            
73 M. Streater, et al.;  J. Med. Chem, 1990, 33, 1749-1755 
74 B.L. Rai, et al.; Tetrahedron, 1999, 55, 1129-1142 
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 Deprotection 
1) The respective ligand was dissolved in an adequate solvent and 10% Pd/C was added. 
The solution was put into the autoclave and the apparatus was flushed with Ar and 
evacuated (3x). H2 gas at a pressure of 10-15 bar was applied and the solution was stirred at 
RT over night. Subsequently the solution was filtered through Celite to remove Pd/C and the 
solvent was removed by rotary evaporation. Recrystallization from 96% ethanol gave the 
pure product. 
 
2) The respective ligand was dissolved in HCl : CH3COOH = 1:1 and stirred at r.t. for 3-4 
days. The mixture of HCl and acetic acid was removed by rotary evaporation and the residue 
was washed with methanol and put on the rotary evaporater to remove acetic acid (3x). 
Recrystallisation from ethanol gave the pure product. 
 
 Complexation 
The ligands were activated by sodium methoxide in methanol. Subsequently the dimer [(η6-
arene)MX(µ-X)]2 (M = Ru, Os, X = Cl, Br, I) was dissolved in dichloromethane and added in 
one portion. The reaction mixture was stirred at RT for a minimum of 3 hours. In some cases 
the solution had to be stirred at 60 °C for a minimum of 4 h. Afterwards the solvent was 
removed by rotary evaporation and put on high vacuum for further drying. Then the product 
was dissolved in dichloromethane, filtered and washed with dichloromethane to remove 
NaOMe. The solution was concentrated on the rotary evaporator. Finally diethyl ether was 
added until precipitation occurred.29 
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4.2.3 Amides 
[Halido(η6-p-cymene){N-[(1-propylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-pyridonato-
κO}ruthenium(II)] – 1 
 
 Amide formation 
 
N-[(1-Propylamide)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone – 1d 
The reaction was performed according to the general procedure, using 3-benzyloxy-1-
carboxymethylpyrid-2-one (4.00 g, 15.4 mmol), TBTU (5.28 g, 16.4 mmol), 4-
methylmorpholine (3.12 g, 30.8 mmol) and propylamine (0.89 g, 6.0 mmol). 
 
Yield: 1.10 g (87%);  
 
1H NMR (500.10 MHz, d4-MeOH): δ = 7.48 (d, 2H, 3J(H,H)=7.3Hz, HBenzene), 7.38 (dd, 1H, 
3J(H,H)=7.4Hz, HBenzene), 7.32 (dd, 1H, 3J(H,H)=7.3Hz, HBenzene), 7.18 (dd, 1H, 3J(H,H)=1.6Hz, 
3J(H,H)=6.9Hz, HPyridone), 6.99 (dd, 1H, 3J(H,H)=1.5Hz, 3J(H,H)=7.6Hz, HPyridone,meta), 6.28 (m, 
1H, HPyridone), 5.12 (s, 1H, O-CH2), 4.66 (s, 2H, N-CH2), 3.19 (t, 2H, 3J(H,H)=7.1Hz, CH2, amide 
moiety), 1.54-1.59 (m, 2H, CH2, amide moiety), 0.96 (t, 3H, 3J(H,H)=7.4Hz, CH3) ppm; 
 
1d’ 
The reaction mixture of 3-benzyloxy-1-carboxymethyl-2-pyridone  (200 mg, 0.75 mmol), 
propylamine (74 mg, 0.91 mmol), N,N'-dicyclohexylcarbodiimide (200 mg, 0.96 mmol), N-
hydroxysuccinimide (102 mg, 0.88 mmol) and 11 ml of DMF was stirred under Ar. 
Diisopropylethylamine (258.5 mg, 2 mmol) was added and the solution was refluxed at 80 °C 
for 16 hours. The solvent was removed on the rotary evaporator and the product was 
recrystallized from isopropanol.  
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 Deprotection 
 
N-[(1-Propylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 1e 
The reaction was performed according to the general procedure – deprotection 1), using 
methanol, N-[(1-propylamide)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone (1.1 g, 3.7 mmol) 
and 10% Pd/C (0.2 g). 
 
Yield: 0.5 g (71%); Mp: 209 – 211 °C 
 
1H NMR (500.10 MHz, d6-DMSO): δ = 8.93 (s, 1H, OH), 8.11 (t, 1H, J=5.4Hz, NH), 7.06 (d, 
1H, 3J(H,H)=6.5Hz, HPyridone), 6.70 (d, 1H, 3J(H,H)=7.2Hz, HPyridone), 6.07 (t, 1H, 
3J(H,H)=6.7Hz, HPyridone,meta), 4.53 (s, 2H, N-CH2-CO), 3.04 (q, 2H, 3J(H,H)=6.5Hz, CH2, amide 
moiety), 1.43 (m, 2H, CH2, amide moiety), 0.86 (t, 3H, 3J(H,H)=7.2Hz, CH3) ppm;  
 
 Complexation 
 
[Chlorido(η6-p-cymene){N-[(1-propylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 1f 
The reaction was performed according to the general procedure, using N-[(1-
propylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (101 mg, 0.48 mmol), NaOMe (32 
mg, 0.6 mmol) and [(η6-cymene)RuCl(µ-Cl)]2 (123 mg, 0.2 mmol). 
 
Yield: 115 mg (60%); Mp: 137 – 142 °C 
 
1H NMR (500.10 MHz, d4-MeOH): δ = 8.18 (s, 1H, NH), 6.83 (m, 1H, HPyridone),  6.71 (m, 1H, 
HPyridone), 6.39 (m, 1H, HPyridone), 5.67 (m, 2H, Hcymene), 5.45 (m, 2H, Hcymene), 4.66 (s, 1H, N-
CH2-CO), 3.20 (m, 2H, CH2, amide moiety), 2.89 (m, 1H, CH-CH3, cymene), 2.27 (s, 3H, CH3, cymene), 
1.54-1.64 (m, 6H, CH-CH3, cymene), 1.34 (m, 2H, CH2, amide moiety), 0.97 (m, 3H, CH3, amide moiety) 
ppm; 
 
Elemental analysis, Anal.Calc. for C20H27O3N2RuCl·0.25CH2Cl2: C 48.53, H 5.53, N 5.59. 
Found: C 48.31, H 5.22, N 5.94 %.   
 
 
  
 57 
 
[Iodido(η6-p-cymene){N-[(1-propylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-pyridonato-
κO}ruthenium(II)] – 1f’ 
The reaction was performed according to the general procedure, using N-[(1-
propylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (70 mg, 0.33 mmol), NaOMe (24 
mg, 0.45 mmol) and [(η6-cymene)RuI(µ-I)]2 (120 mg, 0.15 mmol). 
 
Yield: 15 mg (9%) 
 
1H NMR (500.10 MHz, d4-MeOH): δ = 6.81 (brs, 1H, HPyridone),  6.65 (brs, 1H, HPyridone), 6.35 
(brs, 1H, HPyridone), 5.69 (brs, 2H, Hcymene), 5.47 (brs, 2H, Hcymene), 4.66 (s, 1H, NH-CH2-CO), 
3.15 (s, 2 H, NH-CH2-CO), 2.92 (brs, 1H, CH-CH3, cymene), 2.27 (s, 3H, CH3, cymene), 1.58 (m, 
2H, CH2-CH3), 1.34 (m, 6H, CH(CH3)2), 0.97 (t, J=7.0 Hz, CH3) ppm; 
 
Elemental analysis, Anal.Calc. for C20H27O3N2RuI*0.25CH2Cl2: C 41.03, H 4.68, N 4.73. 
Found: C 41.08, H 4.47, N 4.46 %.   
 
[Bromido(η6-p-cymene){N-[(1-propylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 1f’’ 
The reaction was performed according to the general procedure, using N-[(1-
propylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (70 mg, 0.33 mmol), NaOMe (24 
mg, 0.45 mmol) and [(η6-cymene)RuBr(µ-Br)]2 (106 mg, 0.15 mmol). 
 
Yield: 15 mg (10%) 
 
1H NMR (500.10 MHz, d4-MeOH): δ = 6.79-6.83 (m, 1H, HPyridone),  6.60-6.70 (m, 1H, 
HPyridone), 6.30-6.40 (m, 1H, HPyridone), 5.62 (d, 2H, 3J(H,H)=5.4Hz, Hcymene), 5.41-5.42 (m, 2H, 
Hcymene), 4.66 (s, 1H, NH-CH2-CO), 3.21-3.24 (m, 2H, CH2, amide moiety), 2.81-2.90 (m, 1H, CH-
CH3, cymene), 2.27 (s, 3H, CH3, cymene), 1.54-1.64 (m, 6H, -CH-CH3, cymene), 1.33-1.37 (m, 2H, 
CH2, amide moiety), 0.91-1.00 (m, 3H, CH3, amide moiety) ppm; 
 
Elemental analysis, Anal.Calc. for C20H27O3N2RuCl·0.25CH2Cl2: C 48.53, H 5.53, N 5.59. 
Found: C 48.31, H 5.22, N 5.94 %.    
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[Halido(η6-p-cymene){N-[(4-morpholinoaniline)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 2 
 
 Amide formation 
 
N-[(4-Morpholinoaniline)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone  - 2d 
 
The reaction was performed according to the general procedure, using 3-benzyloxy-1-
carboxymethylpyrid-2-one (2.0 g, 7.5 mmol), TBTU (2.6 g, 8 mmol), 4-methylmorpholine (1.5 
g, 15 mmol) and 4-morpholinoaniline (1.4 g, 7.5 mmol). 
 
Yield: 2.1 g (66%); Mp: 211 - 212 °C 
 
1H-NMR (500.10 MHz, d6-DMSO) δ = 10.11 (s, 1H, NH), 7.39-7.46 (m, 6H, Hbenzene), 7.27 
(dd, 1H, J=1.5Hz, J=6.9Hz, HPyridone), 6.95 (dd, 1H, J=1.5Hz, J=7.5Hz, HPyridone), 6.91 (d, 2H, 
J=9.1Hz, HBenzene), 6.15 (t, 1H, J=7.1Hz, HPyridone), 5.03 (m, 2H, O-CH2-),  4.72 (m, 2H, N-CH2-
CO)  3.73 (m, 4H, CH2-O), 3.05 (m, 4H, CH2) ppm;  
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 165.4 (-C=O), 157.6 (-C=O), 148.3 (-CO-Bz), 147.7 
(-C-N), 137.1 (-C-O-Bz), 132.0 (CHarom), 131.6 (-C-N), 128.9 (CHarom), 128.43 (CHarom), 
128.39 (CHarom), 120.5 (CHarom), 116.3 (CHarom),  115.9 (CHarom), 103.9 (CHarom), 70.3 (O-CH2-
Bn), 66.6 (-CH2Omorph), 52.3 (N-CH2-CO), 49.3 (CH2-Nmorph) ppm;  
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 Deprotection 
 
N-[(4-Morpholinoaniline)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 2e 
 
The reaction was performed according to the general procedure – deprotection 1), using 
acetic acid, N-[(4-morpholinoaniline)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone (2.0 g, 
4.78 mmol) and 10% Pd/C (0.5 g). 
 
Yield: 1.1 g (72%); Mp: 246 – 247 °C 
 
1H-NMR (500.10 MHz, d6-DMSO), δ = 10.10 (s, 1H, NH), 8.99 (s, 1H, OH), 7.45 (d, 1H, 
3J(H,H)=9.0Hz, Hbenzene), 7.14 (dd, 1H, 3J(H,H)=1.4Hz, 3J(H,H)=6.8Hz, HPyridone), 6.91 (d, 1H, 
3J(H,H)=9.0Hz, Hbenzene), 6.74 (dd, 1H, 3J(H,H)=1.5Hz, 3J(H,H)=7.2Hz, HPyridone), 6.11 (t, 1H, 
3J(H,H)=7.0 Hz, HPyridone), 4.73 (s, 2H, N-CH2-CO), 3.73 (m, 2H, CH2-O), 3.05 (m, 2H, CH2-N) 
ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 165.4 (-C=O), 158.4 (-C=O), 147.7 (-C-OH), 147.1 (-
C-N), 131.5 (-C-N), 130.1 (CHarom), 120.5 (CHarom),  120.5 (CHarom), 115.9 (CHarom),  115.6 
(CHarom), 105.1 (CHarom), 66.6 (-CH2Omorph), 52.2 (N-CH2-CO), 49.3 (-CH2N), ppm;  
 
 
 Complexation 
 
[Chlorido(η6-p-cymene){N-[(4-morpholinoaniline)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 2f 
 
The reaction was performed according to the general procedure, using N-[(4-
morpholineamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (145 mg, 0.44 mmol), NaOMe 
(32 mg, 0.60 mmol) and [(η6-cymene)RuCl(µ-Cl)]2 (123 mg, 0.20 mmol). 
 
Yield: 155 mg (64%); Mp: Decomposition at 241 - 244 °C 
 
1H-NMR (500.10 MHz, CDCl3): δ = 8.06 (s, 1H, NH), 7.60 (d, 1H, J=8.9Hz, Hbenzene), 6.85 (d, 
1H, 3J(H,H)=8.9Hz, Hbenzene), 6.69 (d, 1H, 3J(H,H)=7.7Hz, HPyridone), 6.52 (d, 1H 3J(H,H)=6.1 
Hz, HPyridone), 6.31 (m, 1H, HPyridone), 5.55 (t, 2H, 3J(H,H)=5.2Hz, Hcymene) 5.32 (m, 2H, Hcymene), 
5.22 (d, 1H, 3J(H,H)=15.1Hz, N-CH2-CO), 4.35 (d, 1H, 3J(H,H)=15.1Hz, N-CH2-CO), 3.86 (t, 
 60 
 
4H, 3J(H,H)=7.0Hz, O-CH2), 3.10 (t, 4H, 3J(H,H)=7.0Hz, N-CH2), 2.93 (m, 1H, -CH-CH3, 
cymene), 2.32 (s, 3H, CH3, cymene), 1.34 (m, 6H, -CH-CH3, cymene) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 166.1 (-C=O), 163.9 (-C=O), 161.2 (-C-O), 148.4 (-C-
N), 130.3 (-C-N), 122.1 (CHarom),  120.8 (CHarom), 118.0 (CHarom),  115.9 (CHarom),  113.8 
(CHarom), 99.5 (-C-CH3, cymene), 95.0 (-C-CH cymene), 80.1 (-CH- cymene), 80.0 (-CH- cymene), 78.2 (-
CH cymene), 77.7 (-CH- cymene), 66.9 (-CH2-O), 54.4 (N-CH2-CO), 49.7 (-CH2-N), 31.2 (-CH-CH3, 
cymene), 22.5 (-CH-CH3, cymene), 22.3 (-CH-CH3, cymene), 18.5 (-C-CH3, cymene) ppm;  
 
Elemental analysis, Anal.Calc. for C27H32O4N3RuCl: C 54.13, H 5.38, N 7.01. Found: C 
54.18, H 5.24, N 7.04 %. 
 
[Iodido(η6-p-cymene){N-[(4-morpholinoaniline)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 2f’ 
 
The reaction was performed according to the general procedure, using N-[(4-
morpholineamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (109 mg, 0.33 mmol), NaOMe 
(24 mg, 0.45 mmol) and [(η6-cymene)RuI(µ-I)]2 (120 mg, 0.15 mmol). 
 
Yield: 86 mg (41%) 
 
1H-NMR (500.10 MHz, CDCl3): δ = 8.07 (s, 1H, NH), 7.60 (m, 1H, Hbenzene), 6.86 (d, 1H, J= 
8.5Hz, Hbenzene), 6.70 (t, 1H, J=7.7Hz, HPyridone), 6.59 (d, 1H, J=6.2Hz, HPyridone), 6.29-6.36 (m, 
1H, HPyridone), 5.59 (m, 1H, Hcymene), 5.38 (d, 1H, Hcymene), 5.31-5.33 (m, 1H, Hcymene), 4.74 (s, 
1H, N-CH2-CO), 2.94 - 2.99 (m, 1H, -CH-CH3, cymene), 2.36 (m, 3H, CH3, cymene), 1.36 (m, 6H,  -
CH-CH3, cymene) 1.28 (m, 3H, CH3, cymene)  ppm; 
 
Elemental analysis, Anal.Calc. for C27H32O4N3Ru*0.5H2O: C 46.36, H 4.75, N 6.01. Found: C 
46.33, H 4.38, N 6.24 %.   
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[Bromido(η6-p-cymene){N-[(4-morpholinoaniline)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 2f’’ 
The reaction was performed according to the general procedure, using N-
[(morpholineamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (109 mg, 0.33 mmol), NaOMe 
(24 mg, 0.45 mmol) and [(η6-cymene)RuBr(µ-Br)]2 (106 mg, 0.15 mmol). 
 
Yield: 67 mg (35%) 
 
1H-NMR (500.10 MHz, CDCl3): δ = 7.99 (s, 1H, NH), 7.59 (d, 1H, J=8.9Hz, Hbenzene), 6.85 (d, 
1H, 3J(H,H)=8.9Hz, Hbenzene), 6.69 (d, 1H, 3J(H,H)=7.7Hz, HPyridone), 6.52 (d, 1H 
3J(H,H)=6.1Hz, HPyridone), 6.31 (m, 1H, HPyridone), 5.55 (t, 2H, 3J(H,H)=5.2Hz, Hcymene) 5.32 (dd, 
2H, 3J(H,H)=3.6Hz, 3J(H,H)=5.3Hz, Hcymene), 5.21-5.24 (m, 1H, N-CH2-CO), 4.29-4.32 (m, 1H, 
N-CH2-CO), 2.92 - 2.95 (m, 1H, -CH-CH3, cymene), 2.32 (s, 3H, CH3, cymene), 1.34 (m, 6H, 
J=6.4Hz, -CH-CH3, cymene) ppm; 
 
Elemental analysis, Anal.Calc. for C27H32O4N3Ru*0.05 CH2Cl2: C 50.15, H 4.99, N 6.49. 
Found: C 49.86, H 4.78, N 6.81%.   
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[Chlorido(η6-p-cymene){N-[(4-phenylbenzylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 3f 
 
 Amide formation 
 
N-[(4-phenylbenzylamide)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone – 3d 
 
The reaction was performed according to the general procedure, using 3-benzyloxy-1-
carboxymethylpyrid-2-one (1.4g, 5.3 mmol), TBTU (1.8 g, 5.6 mmol), 4-methylmorpholine 
(1.1 g, 10.6 mmol) and 4-phenylbenzylamine (1.0 g, 5.3 mmol). 
 
Yield: 1.6 g (73%); Mp: 203 - 204°C 
 
1H-NMR (500.10 MHz, d6-DMSO): δ = 8.69 (t, 1H, J=5.5Hz, NH), 7.64 (m, 4H, HBenzene), 7.3-
7.5 (m, 10H, HBenzene), 7.25 (d, 1H, J=6.6Hz, HPyridone), 6.94 (d, 1H, J=7.5Hz, HPyridone), 6.14 (t, 
1H, J=7.0Hz, HPyridone), 5.02 (s, 2H, O-CH2), 4.63 (s, 2H, N-CH2-CO) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 167.4 (-C=O), 157.6 (-C=O), 148.4 (-CO-Bz), 140.4 
(-C-), 139-3 (-C-), 138.9 (-C-), 137.1 (-C-), 132.0 (CHarom), 129.4 (CHarom), 128.9 (CHarom), 
128.45 (CHarom), 128.36 (CHarom), 127.8 (CHarom), 127.1 (CHarom), 116.2 (CHarom),  103.9 
(CHarom), 70.3 (O-CH2-), 51.8 (N-CH2-CO) ppm;  
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 Deprotection 
 
N-[(4-phenylbenzylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 3e 
 
The reaction was performed according to the general procedure – deprotection 2), using N-
[(4-phenylbenzylamide)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone (1.6 g, 3.83 mmol) in 
HCl : CH3COOH. 
 
Yield: 0.2 g (72%); Mp: 236 – 237 °C 
 
1H-NMR (500.10 MHz, d6-DMSO), δ = 9.00 (s, 1H, OH) , 8.69 (t, 1H, 3J(H,H)=5.8Hz, NH), 
7.64 (m, 4H, HBenzene) , 7.48 (t, 2H, J=7.7Hz, HBenzene) , 7.37 (m, 3H, HBenzene), 7.12 (dd, 1H, 
J=1.7Hz, J=6.9Hz, HPyridone) , 6.72 (dd, 1H, J=1.7Hz, J=7.2Hz, HPyridone), 6.10 (t, 1H, J=7.0Hz, 
HPyridone), 4.64 (s, 2H, N-CH2-CO) ppm 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 167.3 (-C=O), 158.4 (-C=O), 147.1 (-C-O), 140.4 (-C-
), 139.3 (-C-), 138.9 (-C-), 130.0 (CHarom), 129.4 (CHarom), 128.4 (CHarom), 127.8 (CHarom), 
127.1 (CHarom),  115.4 (CHarom),  105.2 (CHarom), 51.8 (N-CH2-CO) ppm 
 
 Complexation 
 
[Chlorido(η6-p-cymene){N-[(4-phenylbenzylamide)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 3f 
 
The reaction was performed according to the general procedure, using N-[(4-
phenylbenzylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (130 mg, 0.44 mmol), 
NaOMe (32 mg, 0.6 mmol) and [(η6-cymene)RuCl(µ-Cl)]2 (123 mg, 0.2 mmol). 
 
Yield: 153 mg (65%); Mp: Decomposition at 122 - 126 °C 
 
1H-NMR (500.10 MHz, CDCl3): δ = 7.64 (m, 4H, J=7.8Hz, J=14.5Hz, HBenzene), 7.41-7.59 (m, 
9H, HBenzene), 6.69 (d, 1H, J=7.4Hz, HPyridone), 6.48 (d, 1H, J=6.1Hz, HPyridone), 6.29 (dd, 1H, 
J=7.0Hz, J=14.4Hz, HPyridone), 5.55 (t, 2H, 3J(H,H)=5.2Hz, Hcymene) 5.32 (dd, 2H, 
3J(H,H)=3.6Hz, 3J(H,H)=5.3Hz, Hcymene), 4.76 (s, 1H, N-CH2-CO),  2.87-2.96 (m, 1H, -CH-
CH3), 2.32 (s, 3H, CH3, cymene), 1.34 (m, 6H, -CH-CH3, cymene) ppm; 
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The 13C{1H}-NMR (125.75 MHz, CDCl3) was very noisy, because the amount of substance 
was very small: δ = 166.6 (-C=O), 165.8 (-C=O), 140.4 (-C-O), 136.5 (-C-),  128.7 (CHarom), 
127.6 (CHarom), 127.1 (CHarom), 120.8 (CHarom), 118.0 (CHarom), 114.7 (CHarom),  113.8 
(CHarom), 107.7 (CHarom), 101.3 (-C-CH3, cymene), 95.1 (-C-CH-CH3, cymene), 81.3 (-C- cymene), 80.5 
(-C- cymene), 54.4 (N-CH2-CO), 30.5 (-CH-CH3, cymene),  22.5 (-CH-CH3, cymene), 22.3 (-CH-CH3, 
cymene), 18.5 (-C-CH3, cymene) ppm. 
 
Elemental analysis, Anal.Calc. for C29H29O3N2ClRu: C 59.03, H 4.95, N 4.75. Found: C 
58.63, H 5.04, N 4.55 %.   
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[Chlorido(η6-p-cymene){N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-oxo-κO-2-
(1H)-pyridonato-κO}ruthenium(II)] – 4f 
 
 Amide formation 
N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone – 4d 
 
The reaction was performed according to the general procedure, using 3-benzyloxy-1-
carboxymethylpyrid-2-one (2.0 g, 7.5 mmol), TBTU (2.6 g, 8 mmol), 4-methylmorpholine (1.5 
g, 15 mmol) and 4-(3-aminopropyl)morpholine (1.1 g, 7.5 mmol). 
 
Yield: 2.0 g (70%) 
 
1H-NMR (500.10 MHz, d6-DMSO): δ = 8.12 (t, 1H, J=5.5Hz) 1H, NH), 7.19-7.45 (m, 5H, 
Hbenzene), 7.20 (dd, 1H, J=1.6Hz, J=6.9Hz, HPyridone) 6.92 (dd, 1H, J=1.6Hz, J=7.5 Hz, HPyridone), 
6.10-6.13 (m, 1H, HPyridone), 5.00 (s, 2H, O-CH2-Ph), 4.51 (s, 2H, N-CH2-CO), 3.55-3.57 (m, 
4H, CH2-Omorph), 3.10 (m, 2H, CH2), 2.35 (brs, 4H, N-CH2), 2.27-2.30 (m, 2H, CH2), 1.54-1.69 
(m, 2H, CH2) ppm.  
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 Deprotection 
 
N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 4e 
 
The reaction was performed according to the general procedure – deprotection 1), using 
methanol, N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone (2 
g, 5.2 mmol) and 10% Pd/C (400 mg). 
 
Yield: 1.070 g (69%) 
 
1H-NMR (500.10 MHz, d6-DMSO): δ = 8.94 (s, 1H, OH), 8.11 (t, 1H, J=5.5Hz, NH), 7.06 (dd, 
1H, J=1.7Hz, J=6.9Hz, HPyridone), 6.70 (dd, 1H, J=1.7Hz, J=7.2Hz, HPyridone), 6.07 (t, 1H, 
J=7.0Hz, HPyridone), 4.53 (s, 2H, N-CH2-CO), 3.56-3.58 (m, 4H, CH2-Omorpholine), 3.11 (m, 2H, 
CH2), 2.29-2.30 (m, 2H, CH2), 2.35 (brs, 4H, CH2Nmorph) 1.54-1.60 (m, 2H, CH2) ppm 
 
 
 Complexation 
 
[Chlorido(η6-p-cymene){N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-oxo-κO-2-
(1H)-pyridonato-κO}ruthenium(II)] – 4f 
 
The reaction was performed according to the general procedure, using N-[(4-(3-
aminopropyl)morpholine)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone (130 mg, 0.44 mmol), 
NaOMe (32 mg, 0.60 mmol) and [(η6-cymene)RuCl(µ-Cl)]2 (123 mg, 0.20 mmol). 
 
Yield: 151 mg (67%) 
 
The spectra showed that the compound is not pure.  
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4.2.4 Variation of the Metal-arene moiety of pyridone complexes 
 
Fig. 34: General scheme for metal-arene complexes bearing                                                            
1,2-dimethyl-3-hydroxy-4-(thio)pyridone ligands 
 Ruthenium complexes 
 
[Ru(η6-toluene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 5 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (92 mg, 0.66 mmol), NaOMe (39 mg, 0.72 mmol) and [(η6-
toluene)RuCl(µ-Cl)]2 (158 mg, 0.30 mmol). 
 
1H-NMR (500.10 MHz, d4-D2O): δ = 7.40 (d, 1H, J=6.8Hz, HPyridone), 6.49 (d, 1H, J=6.8Hz, 
HPyridone), 5.82 (t, 2H, J=5.7Hz, HToluene), 5.60 (t, 1H, J=5.5Hz HToluene, tip), 5.42 (d, 2H, J=5.9Hz 
HToluene), 3.79 (s, 3H, N-CH3), 2.48 (s, 3H, CH3), 2.27 (s, 3H, CH3, Toluene) ppm 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 173.7 (-C=O), 158.8 (-C-O-), 134.9 (-C-CH3, Pyridone), 
134.0 (CHPyridone), 108.8 (CHPyridone), 83.6 (CHToluene), 76.1 (CHToluene), 75.4 (CHToluene), 41.7 (N-
CH3), 17.3 (CH3, Toluene), 10.7 (CH3, Pyridone) ppm; 
 
 
[Ru(η6-biphenyl){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 6  
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (92 mg, 0.66 mmol), NaOMe (39 mg, 0.72 mmol) and [(η6-
biphenyl)RuCl(µ-Cl)]2 (196 mg, 0.30 mmol). 
 
1H-NMR (500.10 MHz, d4-MeOH): δ = 7.82 (m, 2H, Hbiphenyl, not coordinated), 7.47-7.50 (m, 3H, 
Hbiphenyl, not coordinated), 7.38 (d, 1H, J=6.8Hz, HPyridone), 6.45 (d, 1H, J=6.8Hz, HPyridone), 6.09 (d, 
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2H, J=5.8Hz Hbiphenyl, coordinated), 5.89-5.94 (m, 3H, Hbiphenyl, coordinated) 3.77 (s, 3H, N-CH3), 2.42 
(s, 3H, CH3) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 173.5 (-C=O), 158.7 (-C-O-), 135.1 (-C-CH3, Pyridone), 
133.9 (CHPyridone), 129.2 (CHBiphenyl), 128.49 (CHBiphenyl), 128.46 (CHBiphenyl), 108.8 (CHBiphenyl), 
94.9 (CHBiphenyl), 93.9 (CBiphenyl), 80.3 (CHBiphenyl) 78.3 (CHBiphenyl) 41.6 (N-CH3), 10.6 (CH3, 
Pyridone) ppm; 
 
[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}I] – 7 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (92 mg, 0.66 mmol), NaOMe (39 mg, 0.72 mmol) and [(η6-p-
cymene)RuI(µ-I)]2 (293 mg, 0.30 mmol).  
 
1H-NMR (500.10 MHz, d4-MeOH): δ = 7.35 (d, 1H, J=6.8Hz, HPyridone), 6.43 (d, 1H, J=6.8Hz, 
HPyridone), 5.61 (d, 2H, J=6.1Hz, HCymene), 5.42 (d, 2H, J=6.0Hz, HCymene), 3.77 (s, 3H, N-CH3),  
2.92 (m, 1H, CH-(CH3)2), 2.44 (s, 3H, CH3), 2.34 (s, 3H, CH3), 1.33 (s, 6H, CH3, Cymene) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 174.0 (-C=O), 159.1 (-C-O-), 134.5 (-C-CH3, Pyridone), 
133.6 (CHPyridone), 106.6 (CHPyridone) 100.0 (CCymene), 94.9 (CCymene), 79.1 (CHCymene), 78.3 
(CHCymene), 41.6 (N-CH3), 31.2 (CH-CH3, Cymene), 21.2 (-CH3, Cymene), 18.0 (CH-(CH3)2, Cymene) 
10.7 (C-CH3, Pyridone) ppm; 
 
[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Br] – 8 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (92 mg, 0.66 mmol), NaOMe (39 mg, 0.72 mmol) and [(η6-p-
cymene)RuBr(µ-Br)]2 (237 mg, 0.30 mmol). 
 
1H-NMR (500.10 MHz, CDCl3): δ = 6.92 (d, 1H, J=6.8Hz, HPyridone), 6.41 (d, 1H, J=6.8Hz, 
HPyridone), 5.39-5.52 (m, 4H, HCymene), 3.62 (s, 3H, N-CH3), 2.8(m, 1H, CHCymene) 2.44 (s, 3H, 
CH3), 2.35 (s, 3H, CH3), 1.28-1.33 (m, 6H, CH3, Cymene) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 173.7 (-C=O), 159.0 (-C-O-), 134.7 (-C-CH3, Pyridone), 
133.8 (CHPyridone), 108.7 (CHPyridone), 98.8 (CCymene), 95.4 (CCymene), 79.1 (CHCymene), 77.7 
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(CHCymene), 41.6 (N-CH3), 31.0 (CH-CH3, Cymene), 21.2 (CH-CH3, Cymene), 17.3 (CHCymene) 10.6 
(C-CH3, Pyridone) ppm; 
 
Elemental analysis, Anal.Calc. for C12H11O3ClRu: C 45.04, H 4.89, N 3.09. Found: C 44.80, H 
4.67, N 3.07 %.   
 
[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-thiopyridone}Cl] – 9 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-thiopyridone (69 mg, 0.44 mmol), NaOMe (32 mg, 0.6 mmol) and [(η6-p-
cymene)RuCl(µ-Cl)]2 (123 mg, 0.6 mmol). 
 
1H-NMR (500.10 MHz, d4-MeOH): δ = 7.51 (d, 1H, J=6.3Hz, HPyridone), 7.38 (d, 1H, J=6.2Hz, 
HPyridone), 5.82 (d, 1H, J=5.8Hz, HCymene), 5.72 (d, 1H, J=5.9Hz, HCymene), 5.50-5.56 (m, 2H, 
HCymene), 4.01 (s, 3H, N-CH3),  2.77 (m, 1H, CH-CH3,Cymene), 2.37 (s, 3H, CH3), 2.23 (s, 3H, 
CH3), 1.27 (d, 3H, J=6.9Hz, CH3, Cymene), 1.15 (d, 3H, J=6.9Hz, CH3, Cymene) ppm; 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 172.4 (-C=S), 146.2 (-C-O-), 141.4 (-C-CH3, Pyridone), 
128.5 (CHPyridone), 128.3 (CHPyridone), 107.2 (CCymene), 101.8 (CCymene), 86.3 (CCymene), 84.2 
(CCymene), 83.9 (CHCymene), 82.1 (CHCymene), 43.9 (N-CH3), 30.6 (CH-CH3, Cymene), 21.4 (CH-CH3, 
Cymene), 20.9 (CH-CH3, Cymene), 17.2 (C-CH3, Cymene) 11.1 (C-CH3, Pyridone) ppm; 
 
[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 10 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (62 mg, 0.44 mmol), NaOMe (32 mg, 0.6 mmol) and [(η6-
cymene)RuCl(µ-Cl)]2 (123 mg, 0.6 mmol). 
 
1H-NMR (500.10 MHz, CDCl3): δ = 7.39 (d, 1H, J=6.8Hz, HPyridone), 6.48 (d, 1H, J=6.8Hz, 
HPyridone), 5.66 (d, 2H, J=6.1Hz, HCymene), 5.44 (d, 2H, J=6.0Hz, HCymene), 3.78 (s, 3H, N-CH3),  
2.86 (m, 1H, CH-CH3,Cymene), 2.47 (s, 3H, CH3), 2.27 (s, 3H, CH3), 1.33 (d, 6H, J=6.9Hz, CH3, 
Cymene) ppm 
 
13C{1H}-NMR (125.75 MHz, CDCl3): δ = 173.7 (-C=O), 158.9 (-C-O-), 134.8 (-C-CH3, Pyridone), 
133.8 (CHPyridone), 108.7 (CHPyridone), 98.5 (CCymene), 95.6 (CCymene), 79.2 (CHCymene), 77.5 
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(CHCymene), 41.6 (N-CH3), 31.0 (CH-CH3, Cymene), 21.1 (CH-CH3, Cymene), 17.1 (-C-CH3, Cymene) 
10.6 (C-CH3, Pyridone) ppm 
 
Elemental analysis, Anal.Calc. for C12H11O3ClRu: C 49.94, H 5.42, N 3.43. Found: C 49.70, H 
5.19, N 3.37 %.   
 
 Osmium complex 
 
[Os(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 11 
 
The reaction was performed according to the general procedure, using 1,2-dimethyl-3-
hydroxy-4(1H)-pyridone (61 mg, 0.40 mmol), NaOMe (27 mg, 0.50 mmol) and [(η6-p-
cymene)OsCl(µ-Cl)]2 (158 mg, 0.20 mmol).  
 
1H-NMR (500.10 MHz, CDCl3): δ = 6.99 (d, 1H, J=6.8Hz, HPyridone), 6.51 (d, 1H, J=6.8Hz, 
HPyridone), 6.00 (d, 1H, J=5.2Hz, HCymene), 5.93 (d, 1H, J=5.1Hz, HCymene), 5.78 (d, 1H, J=5.2Hz, 
HCymene), 5.73 (d, 1H, J=5.2Hz, HCymene), 3.67 (s, 3H, N-CH3),  2.74 (m, 1H, CH-CH3,Cymene), 
2.45 (s, 3H, CH3), 2.37 (s, 3H, CH3), 1.24-1.27 (m, 6H, CH3,Cymene) ppm 
 
Elemental analysis, Anal.Calc. for C17H22NO2OsCl: C 41.00, H 4.45, N: 2.81. Found: C 40.64, 
H 4.18, N 2.94 %.   
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5 Supplementary Data 
 
5.1 1H- and 13C{1H}- NMR spectra 
 
5.1.1 Amides 
N-[(1-propylamide)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone – 1d 
1H-NMR 
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N-[(1-propylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 1e 
1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Iodido(η6-p-cymene){N-[(1-propylamine)carbonylmethyl]-3-oxo-κO-2-(1H)-pyridonato-
κO}ruthenium(II)] – 1f’ 
1H-NMR 
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N-[(morpholinoaniline)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridon  - 2d 
1H-NMR 
 
 
13C{1H}-NMR  
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N-[(morpholinoaniline)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 2e 
1H-NMR 
 
 
13C{1H}-NMR 
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[Chlorido(η6-p-cymene){N-[(morpholinoaniline)carbonylmethyl]-3-oxo-κO-2-(1H)-
pyridonato-κO}ruthenium(II)] – 2f 
1H-NMR  
 
 
13C{1H}-NMR 
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N-[(4-phenylbenzylamide)carbonylmethyl]-3-bezyloxy-2-(1H)-pyridone – 3d 
 
1H-NMR 
 
 
13C{1H}-NMR 
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N-[(4-phenylbenzylamide)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 3e 
 
1H-NMR 
 
 
 
13C{1H}-NMR 
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N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-benzyloxy-2-(1H)-pyridone – 4d 
1H-NMR 
 
 
 
N-[(4-(3-aminopropyl)morpholine)carbonylmethyl]-3-hydroxy-2-(1H)-pyridone – 4e 
1H-NMR  
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5.1.2 Variation of the Metal-arene moiety of pyridone complexes 
 
[Ru(η6-toluene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 5  
1H-NMR  
 
13C{1H}-NMR  
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[Ru(η6-biphenyl){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 6 
 
1H-NMR  
 
 
13C{1H}-NMR  
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[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}I] – 7 
 
1H-NMR  
 
 
13C{1H}-NMR  
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[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-thiopyridone}Cl] – 9 
 
1H-NMR  
 
 
13C{1H}-NMR 
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[Ru(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 10 
 
1H-NMR 
 
 
13C{1H}-NMR  
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[Os(η6-p-cymene){1,2-dimethyl-3-hydroxy-4(1H)-pyridone}Cl] – 11 
1H-NMR 
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